ImmuONE entered the Santander Universities Entrepreneurship Awards representing the University of Hertfordshire. After successfully completing the first two rounds they are through to the semi-finals on the 27th of June.
To deliver therapeutics effectively to the nasal and pulmonary regions, developers must address the physiological barriers in these tissues. This webinar covers how formulation techniques and early in vitro toxicology work together to accelerate development and reduce risk.
In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.
In ImmuBYTES Session 3, “Looking Beyond Baseline Deviations for Lung and Immune Safety,” Prof. Victoria Hutter (CSO & Co-founder) highlighted how subtle changes in macrophage morphology can uncover early immune and lung effects.